Kevin美股成长价投2019-12-31 06:31
$Orgenesis(ORGS)$ $BioLife Solutions(BLFS)$ 近几年美国细胞治疗和再生医学领域发展迅速,投入资本年增长速度超过20%,Orgs为其它公司提供研发服务。算是这波细胞治疗和再生医学淘金热潮里卖铲子的商家。所以近几年公司录的非常稳定而高速的营收增长。股价从高位大幅调整下来,已经开始修复,目...查看全文
牛唐2019-10-11 22:12
$BioLife Solutions(BLFS)$ 全部收购了SAVSU,受益于细胞疗法的火热,2019年收入指引是增长39%,毛利率是七成左右,目前股价回调的厉害,可以关注查看全文
$BioLife Solutions(BLFS)$ 内部交易: 2021-09-28,Chief Quality Officer,Foster Karen A. ,卖出,610普通股, $43.12
$BioLife Solutions(BLFS)$ 内部交易: 2021-09-28,Exec VP & Chief Scientific Off,Mathew Aby J. ,卖出,719普通股, $43.12
$BioLife Solutions(BLFS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001437749-21-022966 Size: 4 KB 网页链接
$BioLife Solutions(BLFS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001437749-21-022967 Size: 4 KB 网页链接
$BioLife Solutions(BLFS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001437749-21-022968 Size: 4 KB 网页链接
$BioLife Solutions(BLFS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001437749-21-022969 Size: 4 KB 网页链接
$BioLife Solutions(BLFS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001437749-21-022970 Size: 4 KB 网页链接
$BioLife Solutions(BLFS)$ 内部交易: 2021-09-27,Chief Quality Officer,Foster Karen A. ,卖出,16332普通股, $44.66
$BioLife Solutions(BLFS)$ 内部交易: 2021-09-27,Chief Quality Officer,Foster Karen A. ,期权,16332普通股, $1.64
$BioLife Solutions(BLFS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001437749-21-022863 Size: 8 KB 网页链接